India is expected to lead Asia‑Pacific in GLP‑1 market growth, with Victoza projected to grow strongly amid an overall segment CAGR of about 11.3% from 2025 to 2030. Growth is driven by rising urban diabetes prevalence, increasing awareness among physicians, and the gradual expansion of private insurance. However, high treatment costs remain a key restraint, limiting access for large sections of the population. The market presents opportunities for generic liraglutide formulations, especially among the expanding middle class. Trends include the rapid rise of telemedicine, mobile health monitoring, and government-backed non-communicable disease programs promoting early intervention.
TABLE - India Victoza Market Size & Forecast By Indication 2021-2033
Indication | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | CAGR (2024-2033) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Type 2 Diabetes | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Obesity Management (Off-Label Use) | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Total | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX |
Source: Company Publications, Primary Interviews, and SR Analysis
TABLE - India Victoza Market Size & Forecast By Distribution Channel 2021-2033
Distribution Channel | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | CAGR (2024-2033) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hospital Pharmacies | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Retail Pharmacies | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Online Pharmacies | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Total | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX |
Source: Company Publications, Primary Interviews, and SR Analysis